The IGF-1R pathway inhibition has been the subject of intensive anti-cancer drug discovery efforts and currently there are more than 30 active clinical trials evaluating anti-IGF-1R targeting agents, either alone or in various combinations (www.clinicaltrial.gov). The gene discussed is IGF1R; the disease is cancer.